Asset Details
Do you wish to reserve the book?
Retrospective Evaluation of Clinical And Follow-Up Outcomes in Primary Cutaneous CD30+ Lymphoproliferative Disorders
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Retrospective Evaluation of Clinical And Follow-Up Outcomes in Primary Cutaneous CD30+ Lymphoproliferative Disorders
Do you wish to request the book?
Retrospective Evaluation of Clinical And Follow-Up Outcomes in Primary Cutaneous CD30+ Lymphoproliferative Disorders
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Retrospective Evaluation of Clinical And Follow-Up Outcomes in Primary Cutaneous CD30+ Lymphoproliferative Disorders
2025
Overview
This study evaluated the demographic data, clinical characteristics, treatment approaches, and treatment responses of 43 patients with primary cutaneous CD30
lymphoproliferative disorders. Lymphomatoid papulosis (LyP) was characterized by predominantly papular (94.1%) and generalized (70.6%) lesions, while primary cutaneous anaplastic large-cell lymphoma (pcALCL) presented with tumoral (77.8%) and solitary (77.8%) lesions (p<0.001). Common treatments for LyP included methotrexate (response rate: 78.5%), topical corticosteroids (response rate: 83.3%), and phototherapy (response rate: 85.8%), but relapse rates were high. In pcALCL, complete remission was achieved with all treatments, with no relapses after brentuximab vedotin (BV). Secondary malignancies were noted in 20.6% of LyP cases. Both LyP and pcALCL had a 100% 5-year disease-specific survival rate, although two LyP patients (5.9%) died of secondary malignancies. In conclusion, LyP and pcALCL are both indolent lymphomas, with LyP being more prone to relapse. BV is effective for resistant pcALCL. LyP patients need long-term monitoring due to the risk of secondary malignancies.
Publisher
Galenos Publishing House,Galenos Publishing,Turkish Society of Hematology
Subject
/ Adult
/ Aged
/ Female
/ Humans
/ Lymphoma
/ Lymphoma, Primary Cutaneous Anaplastic Large Cell - mortality
/ Lymphoma, Primary Cutaneous Anaplastic Large Cell - therapy
/ Lymphomatoid Papulosis - diagnosis
/ Lymphomatoid Papulosis - mortality
/ Lymphomatoid Papulosis - therapy
/ Lymphoproliferative Disorders - diagnosis
/ Lymphoproliferative Disorders - mortality
/ Lymphoproliferative Disorders - therapy
/ Male
/ primary cutaneous anaplastic large-cell lymphoma
/ primary cutaneous cd30+ lymphoproliferative disorders
/ Skin Neoplasms - drug therapy
/ Steroids
